Omar Nadeem

Medical Director, Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute

Appears in 1 story

Last updated Sep 14, 2026

Stories

Teclistamab shows deep remissions in high-risk smoldering myeloma trial

New Capabilities

As of September 2026: Presented ImmunoPRISM results at the EHA Congress, June 2026

Doctors at Dana-Farber Cancer Institute gave teclistamab, a bispecific antibody already approved for advanced myeloma, to 45 patients with high-risk smoldering multiple myeloma. Complete remission followed in 77.8% of them.

Updated Sep 14